SEC Form 4 · accession 0001127602-17-027282
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robin L Washington
Officer — EVP, CFO
Period of report
Sep 7, 2017
Accepted (ET)
Sep 11, 2017 · 8:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 7, 2017 | M | 33,750 | $24.295 | A | 43,352 | D | |
| Common Stock | Sep 7, 2017 | S | 33,750 | $85.00 | D | 9,602 | D | |
| Common Stock | Sep 7, 2017 | S | 18,070 | $85.00 | D | 103,477 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $24.295 | Sep 7, 2017 | M | 33,750 | D | — | Jan 26, 2022 | Common Stock | 33,750 | 0 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.